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Abstract
Background: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)2D3, as well
as 1-hydroxyvitamin D3 to 1a,20-dihydroxyvitamin D3 (1,20(OH)2D3). It also cleaves the side chain of 7-dehydrocholesterol
producing 7-dehydropregnenolone (7DHP), which can be transformed to 20(OH)7DHP. UVB induces transformation of the
steroidal 5,7-dienes to pregnacalciferol (pD) and a lumisterol-like compounds (pL).
Methods and Findings: To define the biological significance of these P450scc-initiated pathways, we tested the effects of
their 5,7-diene precursors and secosteroidal products on leukemia cell differentiation and proliferation in comparison to
1a,25-dihydroxyvitamin D3 (1,25(OH)2D3). These secosteroids inhibited proliferation and induced erythroid differentiation
of K562 human chronic myeloid and MEL mouse leukemia cells with 20(OH)D3 and 20,23(OH)2D3 being either equipotent or
slightly less potent than 1,25(OH)2D3, while 1,20(OH)2D3, pD and pL compounds were slightly or moderately less potent.
The compounds also inhibited proliferation and induced monocytic differentiation of HL-60 promyelocytic and U937
promonocytic human leukemia cells. Among them 1,25(OH)2D3 was the most potent, 20(OH)D3, 20,23(OH)2D3 and
1,20(OH)2D3 were less active, and pD and pL compounds were the least potent. Since it had been previously proven that
secosteroids without the side chain (pD) have no effect on systemic calcium levels we performed additional testing in rats
and found that 20(OH)D3 had no calcemic activity at concentration as high as 1 mg/kg, whereas, 1,20(OH)2D3 was slightly to
moderately calcemic and 1,25(OH)2D3 had strong calcemic activity.
Conclusions: We identified novel secosteroids that are excellent candidates for anti-leukemia therapy with 20(OH)D3
deserving special attention because of its relatively high potency and lack of calcemic activity.
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Introduction
In vivo, vitamin D3 (D3) is generated in the epidermis through
photochemical transformation of 7-dehydrocholesterol (7DHC)
after absorption of ultraviolet radiation B (UVB; wavelength 280–
320 nm) energy [1–4]. The active form of vitamin D3,
1,25(OH)2D3, is generated systemically through sequential 25-
and 1a– hydroxylation in the liver and kidney, respectively [4,5].
It is also produced locally in different organs including skin [5,6].
1,25(OH)2D3, in addition to being a major regulator of body
calcium homeostasis, also inhibits cell proliferation, stimulates
differentiation and/or apoptosis, has tumorostatic and anticarci-
nogenic properties, and protects DNA against oxidative damage
[4,7–10]. Importantly, 1,25(OH)2D3 and its derivatives also
display potent anti-leukemic activities [11–17]. Different leukemia
lines serve as excellent models for testing vitamin D analogs.
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9907Unfortunately, the toxicity (hypercalcemia) of high levels of
vitamin D largely prevents the use of pharmacological doses of
1,25(OH)2D3 for either the prevention or treatment of cancer.
Therefore, there is a continuing search to find vitamin D
analogues (for example, Gemini analogs) that retain antiprolifer-
ative activity but that are non-calcemic, acting as partial receptor
agonists for the VDR [18–20]. In addition, more than 30 years
ago Holick et al showed that shortening the side chain of vitamin
D or eliminating it (producing 20-hydroxypregnacalciferol
(20(OH)pD), attenuates or eliminates the calcemic effect [21].
Cytochrome P450scc hydroxylates vitamin D3 in a sequential
manner, predominantly to 20-hydroxyvitamin D3 (20(OH)D3).
Although further hydroxylation producing 20,23(OH)2D3 and other
metabolites also occurs, these hydroxy-derivatives represent a
minority of reaction products [22–25]. 20(OH)D3 can also be
produced by P450scc in purified adrenal mitochondria [22] and acts
as a potent inducer of keratinocytes differentiation [26] and inhibitor
of NF-kB activity [27]. P450scc also hydroxylates 1-hydroxyvitamin
D3 to 1,20-dihydroxyvitamin D3 (1,20(OH)2D3) a product that
shows antiproliferative activity towards human keratinocytes [28].
Finally, P450scc in vitro or ex-vivo in adrenal glands, cleaves the side
chain of 7-dehydrocholesterol (7DHC) producing 7-dehydropregne-
nolone (7DHP), which can undergo further oxidations by steroido-
genic enzymes [29,30]. 7DHP and it hydroxyderivatives, can
undergo UVB-induced transformation to corresponding pregnacal-
ciferol (pD) and lumisterol-like (pL) compounds [30–32]. These
secosteroids with only a two-carbon side chain (pD and 20(OH)pD)
have been shown to lack calcemic activity in vivo [21].
Thus, having a large panel of novel secosteroidal compounds
that can be biologically active but do not have a side chain or have
a side chain modified at C20 (similar to the Gemini type
analogues), we decided to test whether any of these novel
compounds could act as relatively non-toxic anti-leukemic agents.
Results
1. Structures and origin of novel secosteroids (see Figure
S1)
Vitamin D3, produced through photolytic transformation of 7-
DHC, is hydroxylated to 1,25(OH)2D3 (calcitriol) by the
sequential actions of 25- and 1a-hydroxylases [8]. Vitamin D3 is
also hydroxylated by P450scc to 20(OH)D3 and 20,23(OH)2D3
[22,23], while 1,20(OH)2D3 is generated through hydroxylation of
1(OH)D3 by P450scc [28] or by the action of 1a-hydroxylase on
20(OH)D3 [33]. 20(OH)D3 can also derive from UVB induced
photolytic transformation of 20(OH)7DHC that is produced by
hydroxylation of 7DHC by P450scc [29]. 20(OH)7DHC is further
transformed to 7DHP by P450scc [29,30] then after absorption of
UVB photons forms pD or pL depending on the UV energy [32].
7DHP is potentially reduced by 20-hydroxysteroid dehydrogenase
to 20(OH)7DHP [30] which undergoes UVB induced transfor-
mation to 20(OH)pD [31].
2. Novel secosteroids have low calcemic effect
One of us (MFH) has documented that elimination of all but
two carbons of the side chain in vitamin D3, leading to production
of 20(OH)pD and pD, eliminates the calcemic effect of the
secosteroid [21]. Since P450scc hydroxylates the side chain of D3
and 1(OH)D3 at C20, we tested the calcemic effects of the
resulting products in rats at a doses 0.1 mg/kg–3 mg/kg of body
weight (Fig. 1). 20(OH)D3 at dose as high as 3.0 mg/kg had no
calcemic activity (calcium = 10.461.5 vs 9.361.3 mg/dL for
control), whereas 1,25(OH)2D3 at the same dose had the expected
strong calcemic effect raising calcium to 16.061.2 mg/dL.
Interestingly, addition of a 1a-hydroxyl group to 20(OH)D3
promoted calcemic activity raising calcium to 13.960.8 mg/dL.
Thus for 20(OH)D3, the lack of 1a-hydroxylation underlies its
Figure 1. 20(OH)D3 and 1,20(OH)2D3 have less calcemic effect in comparison to 1,25(OH)2D3. In vivo testing of calcemic effects of
20(OH)D3 and 1,20(OH)2D3 in comparison to 1,25(OH)2D3.
doi:10.1371/journal.pone.0009907.g001
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calcemic effect, however less than that of 1,25(OH)2D3. This is
consistent with a fundamental role of the hydroxyl group at the 1
alpha-position of vitamin D for the regulation of serum calcium
levels [8,21].
3. Novel secosteroidal products show anti-leukemic
activity
Anti-leukemiceffects of 20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3,
pD, 20OHpD and pL in comparison to 1,25(OH)2D3 and to
precursor steroidal 5,7-dienes (for structures see Figure S1), were
tested in K562 human chronic myeloid and MEL mouse
erytholeukemia and human HL-60 promyelocytic and U937
promonocytic leukemia cells. The choice of 10
27 Ma st h e
concentration of drugs to use in the majority of experiments was
based on initial experiments (not shown) as well as on already
published data [26,27,31,34], demonstrating that this concentration
is optimal for comparative studies.
Cell proliferation. The secosteroids inhibited cell
proliferation, however, with different potencies in different cell
lines. Specifically, in mouse (Mel) erythroleukemia the strongest
inhibitory effects were seen for both 1,25(OH)2D3 and
20,23(OH)2D3 with slightly lower (p,0.05) but strong effects for
20(OH)D3 (p,0.01) (Fig. 2A) (Table S1A). 1,20(OH)2D3 was less
potent than 20(OH)D3 (p,0.05), however, more potent than pD,
pL, and 7DHP (p,0.05), while 20(OH)pD and 20(OH)7DHP had
no effect (Table S1A). The latter compounds were less efficient
than 1,25(OH)2D3, 20,23(OH)2D3 and 20(OH)D3 (p,0.05 or
0.01) (Table S1A).
1,25(OH)2D3 and 20,23(OH)2D3 were the most effective in
inhibiting proliferation of K562 human myeloid leukemia while
slightly lower (p,0.05) but highly significant inhibition was seen
for 20(OH)D3 (p,0.01) (Fig. 2B) (Table S1B). 1,20(OH)2D3 and
pL were least potent, and 7DHP, 20(OH)7DHP and 20(OH)pD
had no effect on these cells (Table S1B). Interestingly pD had a
significant inhibitory effect on proliferation, which was not
statistically different from the effects of 1,25(OH)2D3,
20,23(OH)2D3, 20(OH)D3 and 1,20(OH)2D3.
In human HL-60 promyelocytic and U937 myeloid leukemia all
of the secosteroids and steroidal 5.7-dienes showed statistically
significant inhibitory effects, however, their relative potency were
different for both cell lines (Fig. 2C, D). The relative potency for HL-60
cells was as follows: 1,25(OH)2D3.20(OH)D3=20,23(OH)2D3=
1,20(OH)2D3=20(OH)pD.pD=pL(=7DHP) .20(OH)7DHP
(=7DHP), while for K562 cells it was 1,25(OH)2D3 .20(OH)D3=
1,20(OH)2D3.20,23(OH)2D3=pL=7DHP=20(OH)7DHP.
pD=20(OH)pD, respectively (Fig. 2C, D) (Table S1C, D).
Cell Differentiation. The induction of erythroid
differentiation was evident by the pink-red cell pellet of K562
cells after incubation for 7 days in the presence of secosteroids and
steroidal 5.7-dienes (Fig. S2A). The benzidine staining shows that
hemoglobin synthesis begins at day 2 (data not shown) and
approximately 60%–80% of the cells treated with drugs for 7 days
stained positively for benzidine (Fig. 3C; Fig. S2B). 1,25(OH)2D3,
20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3, pD and pL had similar
potency for induction of differentiation as determined from the
number of benzidine positive cells (Fig. 3; Table S2A). 20(OH)pD,
7DHP and 20(OH)7DHP were significantly less potent than
1,25(OH)2D3, 20(OH)D3 and 20,23(OH)2D3, but of similar in
potency to other compounds tested with the exception of
1,20(OH)2D3 which was more potent than 7DHP (Table S2A).
When the level of differentiation was determined from the relative
concentration of hemoglobin as hemin measured spectrophotomet-
rically in an equal number of cells, all compounds tested induced
significant cell differentiation. 1,25(OH)2D3 was more potent than
other compounds with the sequence of potency being: 1,25(OH)2-
D3.20,23(OH)2D3. 20(OH)D3.pL.pD.1,20(OH)2D3.7DH-
P.20(OH)pD.20(OH)7DHP for K562 cells and 1,25(OH)2-
D3.20,23(OH)2D3.20(OH)D3.1,20(OH)2D3.pL=20(OH)
pD.7DHP=20(OH)7DHP.pD in Mel cells (Fig. 3A and B;
Table S2B, C).
The induction of differentiation of HL-60 and U937 cells
towards monocyte-like morphology was evaluated by NBT
reduction and cell morphology. The first signs of morphological
differentiation were observed at 72 h for all compounds tested
with the differentiation being most pronounced for 1,25(OH)2D3
(data not shown). At day 5, the monocytic maturation pattern was
similar for all compounds (Fig. S3) and by day 7 of treatment 82–
88% of cells were NBT positive. In HL-60 cells 1,25(OH)2D3,
20,23(OH)2D3, 20(OH)D3, 1,20(OH)2D3, pL and pD showed
similar potency in stimulation the formation of NBT positive cells.
20(OH)pD and 5,7-dienes were slightly less potent than vitamin
D3 hydroxyderivatives on day 5 of treatment (Table S2D; Fig. S3).
On Day 7, 1,25(OH)2D3, was equipotent to 20,23(OH)2D3 but
was more efficient in induction of morphological differentiation
than the other compounds tested (Fig. 4A; Table S3E).
20,23(OH)2D3 showed similar potency to 20(OH)D3,
1,20(OH)2D3, pL, pD and 20(OH)7DHP, while 20(OH)pD and
7DHP were less active (Fig. 4A; Table S2E). This was further
confirmed when the absorbance of the supernatants from lysates
was measured at 715 nm (Fig. 4C; Table S2F, G).
In U937 cells, all compounds tested induced cell differentiation
by day 5 of treatment with 20,23(OH)2D3 being more potent than
1,20(OH)2D3, 7DHP, pL, pD and 20(OH)pD (figure not shown;
Table S2H). On day 7, 1,25(OH)2D3 was the most potent
compound, with 20,23(OH)2D3 being more potent than 7DHP,
pL and pD and 20(OH)D3 being more potent than 7DHP (Fig. 4B,
Table S2I). When the level of differentiation was measured
spectrophotometrically to asses the relative effect on an equal
number of cells, on day 5 of treatment all compounds induced
differentiation with the exception of 7DHP and pL. 1,25(OH)2D3,
20(OH)D3 and pD were the most potent with 20(OH)D3 being
significantly more potent than 1,20(OH)2D3, 7DHP, pL and
20(OH)7DHP (Table S2J). On day 7, the strongest induction of
monocyte-like differentiation was observed for 1,25(OH)2D3,
20(OH)D3 and pL with other compounds being less potent, and
7DHP and 20(OH)pD having no effect (Fig. 4D, Table S2K).
4. Real time PCR and flow cytometry studies on HL-60
cells
Secosteroids with a full side chain (1,25(OH)2D3, 20,23(OH)2D3,
20(OH)D3, 1,20(OH)2D3) and those with just a two carbon side
chain (pD and 20(OH)pD) were chosen for further studies on their
antileukemic effects on HL-60 cells. Expression of CD11b and
transferin genes was induced significantly and in a dose dependent
manner only for secosteroids with a full-length side chain
(1,25(OH)2D3, 20,23(OH)2D3, 20(OH)D3 and 1,20(OH)2D3)
(Fig. 5), while pD and 20(OH)pD3 had no or minimal effects (not
shown). These effects on CD11b were confirmed at the protein level
by flow cytometry where 1,25(OH)2D3, 20,23(OH)2D3 and
20(OH)D3 were the strongest inducers of CD11b expression with
1,20(OH)2D3 being less potent and pD and 20(OH)pD3 having no
effect (Fig. 6). Interestingly, among tested compounds only
1,25(OH)2D3 and 1,20(OH)2D3 stimulated CYP24 gene expres-
sion, with 1,20(OH)2D3 showing comparatively low potency (not
shown). For example, at concentration of 10
28M 1,25(OH)2D3
stimulated CYP24 expression 700 times, while 1,20(OH)2D3
stimulated it only 8 times (not shown).
Novel Anti-Leukemic Products
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PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9907Cell cycle analysis showed that secosteroids with a full-length
side chain (1,25(OH)2D3, 20,23(OH)2D3, 20(OH)D3,
1,20(OH)2D3) induced highly significant G1/G0 phase arrest,
while pD and 20(OH)pD were less potent (Fig. 7). Among the
former, 20,23(OH)2D3 was the strongest inducer of arrest at G1/
G0 and the strongest inhibitor of S and G2/M phases
(p,0.05)(Fig. 7).
5. Molecular modeling studies
To understand the potential binding mode of 20S(OH)D3 in
VDR, we selected the crystal structure of the VDR complex with
calcitriol (PDB code: 1DB1)[35]and performed molecular model-
ing studies using Schrodinger Suite 2009 (Schrodinger Inc., New
York, NY). The docking program successfully reproduced the
original binding pose of the native ligand with an excellent docking
score (213.5, Supplemental Fig. S4). All of the six hydrogen
bonding interactions between the ligand and the residues in VDR
are reproduced in this validation: 3-OH to Ser274/Tyr143; 1-OH
to Ser233/Arg270; and 25-OH to His393/HIP301.
Next we examined the potential binding of 20S(OH)D3 to the
VDR. The 20S(OH) isomer (the metabolite generated by P450scc
enzymes) overlaps with the native ligand very well with a docking
score 211.4. We also performed docking calculations for a variety
of D3 metabolites shown in Figure S1. The results are listed in
Table S3. Overall, all the metabolites have good docking score,
suggesting they may bind well to the VDR. In general, metabolites
having 1 alfa-OH have better docking scores than those that do
not have. Shorter chain analogs (pD3 analogs) generally have
worse docking scores, suggesting that the removal of the side chain
may be detrimental to the VDR binding. While we are fully aware
of the limitations with molecular modeling, these docking studies
suggest that there are high binding affinities of these compounds
for the VDR, and the biological activity of these metabolites may
still be generated via their interactions with the VDR.
Discussion
Recently we have provided evidence that the mammalian
P450scc system is capable of sequential hydroxylation of the side
chain of vitamin D3 at position 20 and 23 [22,23,28] to
metabolites that are biologically active in skin cells [26,27,34].
P450scc (in vitro and ex-vivo) can also transform 7DHC to 7DHP
which can be further hydroxylated by classical steroidogenic
enzymes to different steroidal 5,7-dienal hydroxy-products
[29,30]. These, if exposed to UVB, can change to secosteroidal
products with only a 2-carbon side chain [30–32] some of which
are biologically active in skin cells [29,31]. In this study we show
that novel secosteroids and 5,7-dienes, including 20,23(OH)2D3,
20(OH)D3, 1,20(OH)2D3, pD, pL, 20(OH)pD, 7DHP and
20(OH)7DHP, can inhibit proliferation and induce differentiation
of MEL mouse erytholeukemia, human K562 chronic myeloid,
HL-60 promyelocytic and U937 promonocytic leukemia cells,
which is dependent on the cell type and the structure of the
compound tested. These results are consistent with our separate
studies showing that 20(OH)D3, 20,23(OH)2D3 and 1,20(OH)2D3
act in very similar manner to 1,25(OH)2D3 by inhibiting
proliferation and inducing differentiation of cultured human
keratinocytes [26,28,34].
In vivo data shown in Fig. 1 indicate that the calcemic effect of
vitamin D3 derivatives can largely be separated from their other
properties (inhibition of proliferation and stimulation of differen-
tiation) as clearly demonstrated for 20(OH)D3. Interestingly,
removal of the key hydroxyl group at C-1 whose presence is
known to play a role in calcium regulation [5,6,20], has only a
slight or no influence on the induction of differentiation of
monocytes and leukemia cells (20,23(OH)2D3, 20(OH)D3,
1,20(OH)2D3 act in very similar manner (see figures 3–7).
Interestingly, all of the secosteroids we tested had no significant
effect on the induction of CYP24 expression, or a very small effect
in the case of 1,20(OH)2D3, compared to the large stimulation by
1,25(OH)2D3. Again, this observation is in full agreement with our
studies on human keratinocytes, where 20(OH)D3 and
20,23(OH)2D3 have shown poor induction of CYP24, while
having equipotent activity with 1,25(OH)2D3 in the regulation of
cellular phenotype [26,34]. Importantly, gene silencing technology
used on human keratinocytes has clearly demonstrated that the
phenotypic action of 20(OH)D3 and 20,23(OH)2D3 are mediated
through activation of VDR [26,27,34]. Therefore, because of this
intriguing dissociation between phenotypic effects seen in leukemia
cells (present studies) and keratinocytes (parallel studies) we have
examined the potential binding of 20(OH)D3 to the VDR (figure
S4). We have found that the 20S(OH) isomer (the metabolite
generated by P450scc [22,23]) overlaps with the native ligand
(calcitriol) very well having comparable docking score (figure S4).
This opens a new and exciting area to study on the correlation
between structure and activity of P450scc and CYP27A1 and
CYP27B1 generated active vitamin D3 hydroxyderivatives Since
these compounds also differ in the presence or absence of a
hydroxyl group at C-25, we suggest that a C-25 hydroxyl group, in
addition to C-1 (see above), is necessary for strong induction of
CYP24 gene expression. Future studies on this subject are
mandatory, since CYP24 is the major enzyme causing inactivation
of vitamin D, and respectively slower rates of inactivation could be
predicted for the P450scc-derived secosteroids, which should be of
advantage for therapeutic use of these compounds.
The observed activities of the various secosteroids and steroidal
5–7dienes we tested were influenced by the genetic background of
the cell lines used, suggesting the existence of cell-type specific
factors that can modulate activities. Such factors might include the
cocktail of transcription factors present, and the concentration of
vitamin D metabolizing enzymes in the cells such as CYP24,
CYP27A1 and CYP27B1. Despite this variability between cell
types, the non-calcemic 20(OH)D3 and its hydroxyl-derivatives
generally exerted effects on cell proliferation and differentiation
comparable to those of 1,25(OH)2D3. Furthermore we observed
functional similarity with the effects induced by 20(OH)D3 and
20,23(OH)2D3 in epidermal keratinocytes, e.g., G1/G0 arrest
connected with induction of their differentiation program [26,34].
The shortening of the side chain resulted in decreased activity,
which is in agreement with lower docking score in comparison to
1,25(OH)2D3 (Table S3). Nevertheless, these compounds, pD3
and 20-OH pD3, do induce leukemia cell differentiation, similarly
as in melanoma cells [29,31]. This suggests that the mechanism of
action of the tested compounds is conserved among different cell
types including leukemias (cell of hematopoietic origin), normal
skin keratinocytes [26,34] and malignant melanoma cells [29,31].
Figure 2. Novel secosteroids and steroidal 5.7-diene compounds have anti-proliferative effects on leukemia cells. The anti-
proliferative effects of novel secosteroidal and steroidal 5,7-diene compounds on Mel mouse erythroleukemia (A), human K562 myeloid (B), HL-60
human promyelocytic (C), U937 promonocytic (D) leukemias. After treatment for 7 days with different compounds (10
27 M), cells were stained with
trypan blue and the number of viable cells counted. Statistically significant effects are marked as follow *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0009907.g002
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originating from blood cell precursors in bone marrow. Depending
on the lineage of leukemic cells they can be divided into myeloid,
monocytic, erythroid and megakaryocytic. AML is characterized
by accumulation of immature forms (blasts) in bone marrow and
subsequently in peripheral blood and are rapidly and universally
fatal if not treated. Developed over the last three decades,
chemotherapeutic regimens to treat AML markedly improved the
rate of remission and survival in AML patients. However, many
leukemias show primary resistance to current therapy and many
patients suffers from AML relapse following initial remission.
Relapsed disease often becomes resistant to currently available
Figure 3. Novel secosteroids and steroidal 5.7-diene induce erythroid differentiation in leukemia cells. Induction of erythroid
differentiation determined was from the the concentration of hemoglobin in an equal number of cells. Cells were treated for 7 days with different
compounds (10
27 M), stained with benzidine solution and the amount of hemoglobin as hemin in Mel (A) or K562 (B) leukemia cells was determined
by measuring the absorbance at 600 nm after lysis of the cells. ***p,0.001. C.The number of benzidine positive K562 cells after 7 days of treatment
with different compounds (10
27 M). Cells were stained with benzidine solution and the number of benzidine positive (blue) cells was determined by
counting 200 cells per microscopic field. The results are present as % of benzidine positive cells in comparison to total cell number. *p,0.05;
**p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0009907.g003
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9907Figure 4. Novel secosteroids and steroidal 5.7-diene induce monocytic differentiation in HL-60 (A, C) and U937 cells (B, D). A and B.
Cells were treated for 7 days with different compounds (10
27 M), stained with NBT and the number of NBT positive (blue) cells was determined
counting 200 cells per field, and expressed as a % of the total cells. Induction of differentiation measured by the absorbance at 715 nm after lysis of
the equal number of NBT stained cells is in C and D.* p ,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0009907.g004
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9907chemotherapeutic drugs and short of bone marrow transplant such
relapsed patients become incurable and die. These findings
necessitate a continuing search for new drugs or adjuvant
therapeutic approaches to treat AML.It is well established that
hematopoietic cells and their malignant counterparts (leukemic
blasts) express VDR. Moreover, in vitro studies of myeloid
leukemia cells show that there is strong response to the active form
of vitamin D ranging from induction of differentiation to induction
of apoptosis or autophagy, with resulting attenuation of prolifer-
ation [10,12–14,36]. Unfortunately in vivo use of these promising
drugs is limited by their toxic (calcemic) activity. In this study we
report that newly identified and characterized derivatives of
vitamin D that have low or no calcemic activity still retain their
potent anti-leukemic effects. Furthermore, the above compounds
have the potential to be normally generated in skin (from their 5,7-
dienes precursors) exposed to solar radiation [29–31,37]. Poten-
Figure 5. Novel secosteroidal and steroidal 5.7-diene induce the expression of differentiation genes in HL-60 cells. Real time PCR
analysis of the expression of CD11b and transferrin genes in HL-60 cells. Cells were treated for 3 days with graded concentrations of 1,25(OH)2D3 (A),
20(OH)D3 (B), 20,23(OH)2D3 (C) and 1,20(OH)2D3 (D), mRNA was isolated and the gene expression analyzed. *p,0.05; **p,0.01; ***p,0.001
determined with one way ANOVA.
doi:10.1371/journal.pone.0009907.g005
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9907tially these derivatives can be synthesized in other tissues in the
body expressing P450scc, for example the adrenal gland
[22,23,25,30,38]. Interestingly the number of tissues in which
expression of P450scc has been identified is growing and includes
bone, thymus, skin and brain as examples [30,39–44], raising the
possibility of local production of the ligands identified in this study
in the bone marrow environment. Therefore, we believe that we
have identified a family of non-toxic and physiological compounds
that can be used in therapy of acute leukemias [22,23,28–31].
In summary, novel secosteroidal products of P450scc metabo-
lism of vitamin D3 and pro-vitamin D3, show excellent anti-
leukemia activity in vitro with 20(OH)D3 deserving special
attention because of its relatively high potency and lack of
calcemic activity. Moreover, since these compounds potentially
can be synthesized in vivo in adrenal gland or generated by skin
and theoretically may be produced by many other tissues including
bone, further studies are required to define their potential
physiological and pathophysiological role in bone marrow
homeostasis and leukemiagenesis.
Materials and Methods
1. Steroids and secosteroids
Chemical structures of the compounds tested are shown in
Figure S1. 1,25(OH)2D3 was purchased from (Fluka). 20(OH)D3
and 20,23(OH)2D3 were biochemically synthesized as described
Figure 6. Novel secosteroids and steroidal 5.7-diene induce the expression of markers of differentiation in HL-60 cells. Flow
cytometry analysis of CD11b protein expression in HL-60 cells. Cells were treated for 5 days with 10
26 M 1,25(OH)2D3 (A), 20(OH)D3 (B),
20,23(OH)2D3 (C), 1,20(OH)2D3 (D), pD (E) and 20(OH)pD (F), mRNA was isolated and the % of cells expressing CD11b protein determined. *p,0.05;
**p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0009907.g006
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PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9907Figure 7. Novel secosteroids and steroidal 5.7-diene arrest HL-60 cells in G1/G0 phase of the cell cycle. Cell cycle analysis of the HL-60
human promyelocytic human leukemia shows arrest in G1/G0 phase (A). Statistically significant inhibition of S (B) and G2/M (C) phases is also evident
for 1,25(OH)2D3, 20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3 but absent for pD and 20(OH)pD. Representative flow cytometry analysis for 20,23(OH)2D3 is
in D. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0009907.g007
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PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9907previously using an in vitro reconstituted P450scc system with
vitamin D3 (Sigma) as substrate [23,30]. 1,20(OH)2D3 was
biochemically synthesized from 1a-hydroxyvitamin D3 (Sigma)
as described previously [28].The products were purified by TLC
followed by RP-HPLC and identities were confirmed based on
mass and UV spectra, as well as on retention times in comparison
to standards previously characterized by NMR [23,28,30]. The
compounds were aliquoted, dried and stored at 280uC until use.
7DHP and 20(OH)7DHP were synthesized and purified as
described previously [31,32]. After NMR confirmation of their
structures, the steroids were purified by HPLC, aliquoted and
stored for further use or subjected to photochemical transforma-
tion using a Biorad UV Transilluminator 2000 (Biorad, Hercules,
CA). Spectral characteristics of the UVB (280–320 nm) source
were published previously [45,46] and its strength (4.860.2 mW
cm
22) was routinely measured with a digital UVB Meter Model
6.0 (Solartech Inc., Harrison Twp, MI). Irradiation was followed
by incubation for 14 h at room temperature then selected products
were purified by RP-HPLC chromatography as described [31,32].
The major products were identified on the basis of their retention
time and characteristic UV absorption. Initial identification was
confirmed by means of MS and NMR measurements [31,32]. The
resulting secosteroids including pregnacalciferol (pD), pregnalu-
misterol (pL) and 20-hydroxy-pregnacalciferol (20(OH)pD) were
RP-HPLC purified, aliquoted and stored at 280uC [31,32].
2. Testing on leukemia cell lines
MEL mouse erythroleukemia [47], human K562 chronic
myeloid leukemia (purchased from American Tissue Culture
Collection, USA), and human HL-60 human promyelocytic [48]
and U937 promonocytic leukemia [49] cells were cultured in
RPMI 1640 containing 10% fetal bovine serum (FBS) (Atlanta
Biologics)) and 1% penicillin/streptomycin/amphotericin antibi-
otic solution (Sigma) at 37uCi n5 %C O 2. Test compounds were
dissolved in ethanol and added to the cultures to reach final
concentrations as listed. Ethanol at a concentration of 0.1% was
used as a vehicle (negative) control, while 2% DMSO or 32 nM
TPA served as positive controls for studies on cell differentiation.
U937 and MEL cell lines were generous gift from Dr S. Hanissian
(University of Tennessee HSC) and HL-60 from Dr M. Radic
(University of Tennessee HSC).
Cell proliferation. Cells at concentrations of 2610
6 cells/ml
(K56 and MEL lines) and 10
7 cells/ml (HL-60 and U937 lines)
were inoculated into T25 flasks (TPP, Midwest Scientific)
containing 10 ml of RPMI supplemented with charcoal treated
10% FBS. The test compounds were added at concentrations of
10
27 M every day with media being changed every 72 hours.
After 7 days days the cells were stained in 0.4% trypan blue
(Sigma) and the viable cells counted with a hemacytometer.
Cell cycle analysis. Cell cycle analysis was performed by
flow cytometry following standard protocols used in our
laboratories [26,50]. Briefly, HL-60 cells were cultured in RPMI
1640 plus charcoal treated 10% FBS (HyClone). Test compounds
were added to a final concentration 10
26 M in 0.1% ethanol every
day with media being changed every third day. On day five the
cells were washed in PBS, fixed in 70% cold ethanol and stained
with propidium iodine (Sigma). DNA content analysis was
performed with a FACS Calibur flow cytometer.
Cell differentiation. To estimate erythroid differentiation
(production of hemoglobin), first we evaluated the number of
benzidine positive cells after 5 and 7 days in culture. Cells were
centrifuged and washed four times with PBS and resuspended in
1 ml of fresh PBS. For hemoglobin determination, a benzidine
staining solution was freshly prepared by mixing one part of 30%
hydrogen peroxide, one part of base stock solution of 3%
benzidine in 90% acetic acid, and 5 parts of water. The solution
was diluted 1:10 with the cell suspension and 250 ml aliquots
added to 4 wells of a 24-well plate. After 10 min of incubation at
room temperature, benzidine-positive cells were counted under
the microscope with a minimum of 200 cells scored. Second, to
define the relative content of hemoglobin spectrophotometrically
[51], equal number of cells (7610
6) were washed with cold PBS
and lysed for 20 min in 100 ml of lysis buffer (0.2% Triton X-100
in 100 mM potassium phosphate buffer, pH 7.8). The lysates were
centrifuged for 15 min at 1500 r.p.m. and 100 ml of the
supernatant was incubated with 2 ml of benzidine solution
(5 mg/ml in glacial acetic acid) and 2 ml 30% H2O2 for 10 min
at room temperature in the dark. Absorption was measured at
600 nm. Data are shown as fold increases in comparison to the
level of hemoglobin in vehicle-treated cells.
Differentiation of HL-60 or U937 cells toward monocytes-like
morphology and NBT-reduction was assessed after 5 and 7 days.
Cells (2610
6) were washed with PBS four times and resuspended
in 200 ml of NBT solution (4 mg/ml). After the addition of 200 ml
of TPA solution (2 mg/ml in PBS) cells were incubated at 37uC
for 60 min in 24-well plates. Cell differentiation was assessed by
intracellular blue formazan deposits. The NBT positive and
negative cells were scored under light microscopy examination
(206) with a minimum of 200 cells scored. [52]. For
spectrophotometric analysis the cells were washed twice with
buffer containing cold bovine serum albumin solution (17 mg/ml
BSA, 137 mM NaCl, 5 mM KCl, 0.8 mM MgSO4,1 0 m M ,
HEPES, pH 7.4) to remove unreacted NBT, and the insoluble
formazan deposits in the resulting pellets were solubilized in 1 ml
of 90% DMSO, 0.1% SDS and 0.01 mM NaOH by vigorous
vortexing. The samples were centrifuged 5 min at 1,500 x g to
remove the cellular debris, and then the absorbance of
supernatants measured at 715 nm. Data are expressed as change
in A715/10
6 cells [53].
CD11b expression. Staining of the CD11b cell
differentiation marker was carried out according to the
manufacturer’s protocol as follows. Cultured cells were
resuspended in cold wash buffer (PBS supplemented with 1%
FBS and 1% human serum to block non-specific Fc-mediated
binding) at a concentration of 2610
6/ml. After centrifugation,
the cell pellet was resuspended in 100 ml wash buffer. Aliquots
(50 ml) of this were incubated with 50 ml of diluted antibody,
either phycoerythrin-conjugated mouse anti-human CD11b
antibody or phycoerythrin-conjugated mouse IgG isotype as
control (both from BD Pharmingen, San Diego, California). After
30 min the cells were centrifuged at at 400 x g and resuspended
in 1 ml of wash buffer. This step was repeated with cells finally
being resuspended in 200 ml of wash buffer for flow cytometry
[54].
Real-time RT PCR. The RNA from HL-60 cells treated as
described above was isolated using the Absolutely RNA Miniprep
Kit (Stratagene, La Jolla, CA). Reverse transcription (1 mg RNA/
reaction) was performed using the Transcriptor First Strand
cDNA Synthesis Kit (Roche, Mannheim, Germany). Real-time
PCR was performed using undiluted cDNA and a TaqMan PCR
Master Mix. Reactions (in triplicate) were performed at 50uC for
2 min, 95uC for 10 min and then 50 cycles of 95uC for 15 sec,
60uC for 30 sec and 72uC for 30 sec. The primers and probes
were designed with the universal probe library (Roche). Data were
collected on a Roche Light Cycler 480. The amount of amplified
product for each gene was compared to that for b actin using a
comparative CT method. A list of the primers used for RT-PCR
DNA amplification is shown in Table S4.
Novel Anti-Leukemic Products
PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e99073. Testing of calcemic effect
The calcemic effects of 20(OH)D3 and 1,20(OH)2D3 were
compared with 25(OH)D3 and 1,25(OH)2D 3 .B r i e f l y ,w e a n l i n g
rats were obtained from Holtzman and fed a vitamin D
deficient diet for 3 months before they were divided into 13
groups (6 animals per group) and injected with either vehicle
(propylene glycol) or 3 concentrations (0.3 mg/kg, 1.0 mg/kg,
3.0 mg/kg) of 25(OH)D3, 1,25(OH)2D3, 20(OH)D3 or
1,20(OH)2D3 dissolved in propylene glycol for 7 consecutive
days. A day after the final dosing, blood was obtained by heart
puncture and serum was prepared. Serum calcium was
determined by using a kit (DICA-500 QuantiChrom
TM)f r o m
BioAssay Systems (Hayward, CA). Data were analyzed using a
student’s 1-tailed independent t-test with a p value indicating
significance at p,0.05.
4. Statistical analysis
Data were analyzed with GraphPad Prizm Version 4.0
(GraphPad Software Inc., San Diego, CA, USA) using the t-test
or one way ANOVA with appropriate post-hoc tests. Differences
were considered significant when p,0.05. The data are presented
as means 2/+ SE.
Supporting Information
Figure S1 Structures and origin of novel secosteroids. Arrows
show direction of enzymatic reactions or photochemical transfor-
mation. 20HSD: 20-hydroxysteroid dehydrogenase; P40scc:
CYP11A1; 1-alpha hydroxylase: CYP27B1.
Found at: doi:10.1371/journal.pone.0009907.s001 (0.74 MB TIF)
Figure S2 Morphological aspects of erythroid differentiation in
K562 human leukemia after 7 days of treatment with 10
27Mo f
listed compounds. A. Representative cell pellets after 7 days of
treatment with 1,25(OH)2D3 and 20,23(OH)2D3. B. Representa-
tive microscopic fields showing benzidine positive K562 cells. The
cells were stained with benzidine solution and photographed in
light microscopy, 206magnification.
Found at: doi:10.1371/journal.pone.0009907.s002 (0.14 MB
PDF)
Figure S3 Morphological aspects of monocytic differentiation in
HL-60 (A) and U932 (B) human leukemia cells after 5 days of
treatment with 10
27M of listed compounds. The cells were stained
with NBT solution (blue) and photographed in light microscopy,
206magnification.
Found at: doi:10.1371/journal.pone.0009907.s003 (0.22 MB
PDF)
Figure S4 Superimposition of 20S(OH)D3 (dark green, docking
score 211.4) and the native ligands in VDR (docking score
213.5). Yellow dotted lines shows that the docking program well
reproduced the six hydrogen bonding interactions between the
native ligand and VDR that are presented in the crystal structures.
Found at: doi:10.1371/journal.pone.0009907.s004 (0.57 MB TIF)
Table S1 Student t test analysis of inhibitory effect of tested
compounds on leukemia cells proliferation
Found at: doi:10.1371/journal.pone.0009907.s005 (0.11 MB
DOC)
Table S2 Student t test analysis of stimulatory effect of tested
compounds on leukemia differentiation.
Found at: doi:10.1371/journal.pone.0009907.s006 (0.26 MB
DOC)
Table S3 Docking scores of the biding of tested ligands to the
VDR.
Found at: doi:10.1371/journal.pone.0009907.s007 (0.04 MB
DOC)
Table S4 Primers used for real time RT-PCR analysis.
Found at: doi:10.1371/journal.pone.0009907.s008 (0.03 MB
DOC)
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